Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

To assess effectiveness and safety, Eisai sought to include people whose genetic profiles made them especially prone to ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

Issued on behalf of PlantX Life Inc. VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity ... president and head ...